Skip to content

Science Pulse

at Proud ScientistECG · AP · GW

Forum · Medicine · Story discussion

Novel Oral HAE Drug Measures Up to Injectable Options

(MedPage Today) -- Prophylactic use of the novel oral bradykinin B2 receptor antagonist deucrictibant substantially reduced hereditary angioedema (HAE) attacks, a pivotal phase III trial showed. For the primary…

2.9 hours ago — MedPage Today · Read the original

Peer reviews (0)

Comments (0)

No comments yet. Start the discussion.

Loading sign-in…